Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Daratumumab in Relapsed/Refractory Multiple Myeloma
NCT02807454Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Jul 2016
- Primary completion
- Jan 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of durvalumab in multiple myeloma (MM) (2 arms), sponsored by Celgene Corporation. Primary endpoints: Overall Response Rate up to 66 months, Adverse Events up to 58 months and 1 more. Started Jul 2016; status: terminated.
02
Drugs
durvalumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02807454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02807454.